Please provide your email address to receive an email when new articles are posted on . Viloxazine is a noradrenergic/norepinephrine reuptake inhibitor, and trazodone ...
The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...
EEG-based machine learning predicted SSRI treatment response in depression with high accuracy. Learn how brain signals could ...
This is the first installment in a series of articles about the science of various aspects of college life. Use of selective serotonin reuptake inhibitors, or SSRIs, has increased among college ...
Taking certain antidepressants at the time of a traumatic brain injury (TBI) is not associated with an increased risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results